Immunogenicity of the BNT162b2 vaccine in frail or disabled nursing home residents: COVID-A study.

Sergio Salmerón RíosMarta Mas RomeroElisa Belén Cortés ZamoraMaría Teresa Tabernero SahuquilloLuis Romero RizosPedro Manuel Sánchez-JuradoGinés Sánchez-NievasJosé Joaquín Blas SeñaladaInmaculada García NoguerasJuan de Dios Estrella CazallaFernando Andrés-PretelAntonio Murillo RomeroVolker Martin LauschkeJustin StebbingPedro Abizanda Soler

Published in: Journal of the American Geriatrics Society (2021)

The BNT162b2 mRNA COVID-19 vaccine in older adults is safe and produces immunogenicity, independently of the frailty and disability profiles. Older adults in LTCFs should receive a COVID-19 vaccine.

Keyphrases

coronavirus disease
sars cov
physical activity
respiratory syndrome coronavirus
multiple sclerosis
community dwelling